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Trained immunity and cardiovascular disease:
is it time for translation to humans?
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Commentary on: ‘Metabolic induction of trained immunity
through themevalonate pathway’ byBekkering et al.,Cell 20187;
‘Modulation of myelopoiesis progenitors is an integral compo-
nent of trained immunity’ byMitroulis et al.,Cell 20188;
‘BCG educates hematopoietic stem cells to generate protec-
tive innate immunity against tuberculosis’ by Kaufmann et al.,
Cell 20189;
‘Western diet triggers NLRP3-dependent innate immune
reprogramming’ by Christ et al.,Cell 2018.10
One of the major achievements in the last few years in the field of immu-
nology was the discovery that monocytes, macrophages and natural
killer cells can retain ‘memory’ of previous infections (trained cells) and
may exhibit an increased responsiveness upon re-challenge with an insult
similar or unrelated to the first one.1 This process results in enhanced
cytokine production and provides a more effective protection against re-
infection. Epigenetic reprogramming is the key mechanism supporting
the acquisition of trained immunity, with selective changes in histone
methylation and acetylation associated with the acquisition of a trained
phenotype.2
How does the first insult induce changes in the epigenetic signature?
During trained immunity, monocytes and macrophages undergo a rapid
shift in intracellular metabolism following incubation with ß-glucan
(a prototypical trained immunity inducing agonist).3 Resting monocytes
and macrophages mainly use oxidative phosphorylation, but during
innate immune training, these cells shift toward aerobic glycolysis, a
process able to sustain the metabolic needs associated with cell activa-
tion/expansion. Immunometabolic reprogramming, therefore, plays a
key role in shaping the immune response.4
Is trained immunity relevant in atherosclerosis? In vitro data indicate
that exposure of monocytes to oxidized LDL induces the enrichment of
histone methylation (H3K4me3) in the promoter of several pro-
inflammatory genes, including IL6, MCP1, IL8, TNFa, MMP2 and MMP9
that, upon re-challenging, results in an increased production of these
cytokines and metalloproteases.5 Lipoprotein (a) [Lp(a)] can also induce
trained immunity, an effect related to the oxidized phospholipids carried
by this lipoprotein.6 The trained phenotype of macrophages observed
under these conditions supports the existence of a yin/yang effect:
trained immunity is protective toward infections but is deleterious in the
context of atherosclerosis. A series of additional questions arises from
these observations: (i) why do sterile inflammatory factors induce
trained immunity?; (ii) is aerobic glycolysis the only metabolic pathway
involved in this process?; (iii) given that trained immunity appears to be a
long term effect (up to months), how might this fit with the relatively
short lifespan of monocytes?
Recent observations from the International Trained Immunity
Consortium have contributed to address most of these aspects.7–10
Bekkering et al.7 showed that the mevalonate pathway is crucially
involved in the training of myeloid cells induced by several stimuli. This
effect is prevented by statins but not by a squalene synthase inhibitor,
suggesting that an intermediate of cholesterol biosynthetic pathway,
rather than cholesterol itself, induces trained immunity.7 Indeed, they
showed that mevalonate enhances IGF-1 receptor signalling, mTOR acti-
vation, glycolysis and epigenetic reprogramming under inflammatory
conditions.7 Mitroulis et al.8 reported that ß-glucan induces the expan-
sion of myeloid cell precursors already in the bone marrow, by targeting
several pathways associated with cell proliferation, cholesterol biosyn-
thesis and glycolysis. This effect depends on the increased production of
IL-1ß and granulocyte-macrophage colony stimulating factor (GM-CSF),
which in turn activates a STAT5-dependent pathway.8 These trained
hematopoietic precursors are then more effective in protecting toward
chemotherapy-induced DNA damage and cell death.8 Similar observa-
tions were reported by Kaufmann et al.,9 who explored the effect of
Bacillus Calmette-Gue´rin (BCG)-induced training on the protection
toward mycobacterium tuberculosis and identified IFNc signalling as crit-
ically involved in this effect. Christ et al.10 investigated whether and how
a cholesterol rich diet may induce trained immunity in a mouse model of
hypercholesterolaemia and atherosclerosis (the LDLR KO mouse). The
activation of the NLRP3 inflammasome was found to play a key role in
this process, but, in spite of the extensive characterization of myeloid
progenitor cells in this atheroprone mouse model, Christ et al. did not
address whether trained immunity may impact atherosclerotic plaque
development.10 Such a study will be crucial to ‘close the circle’ and cau-
sally link trained immunity tuning with atherogenesis.
Are we ready to move trained immunity in the clinical setting for the
treatment of cardiovascular disease? Patients with mevalonate kinase
deficiency, who accumulate mevalonate in monocytes, present a constit-
utive trained immunity phenotype,7 but the overlap of epigenetic
changes with those reported in in vitro trained cells is minimal.
* Corresponding author. Tel: þ392 503 18313; fax: þ392 503 18386, E-mail: danilo.norata@unimi.it
Published on behalf of the European Society of Cardiology. All rights reserved. VC The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.
Cardiovascular Research (2018) 114, e41–e42
doi:10.1093/cvr/cvy043 EDITORS’ CORNER
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/114/6/e41/4974437 by U
niversità degli Studi di M
ilano user on 09 January 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Epigenetics maymediate the effects of environmental risk factors on car-
diovascular disease, and, for instance, a methylome analysis has shown a
clear impact of epigenome changes on inflammatory vascular remodeling.11
Moreover, epigenomic and transcriptomic approaches are now considered
crucial to identify novel targets for diagnosis and therapy of the ischaemic
heart.12 However, contrary to the expectations, the activating histone
methylation marker of trained immunity (H3K4me3) was reduced in the
promoter of pro-inflammatory genes (TNFa, IL-6, IL-1ß) in monocytes
from patients with symptomatic atherosclerosis compared with controls.13
These findings support the need for a more comprehensive characteriza-
tion of the trained immune cell epigenetic signature in the ‘real world’.
The detailed molecular characterization by Bekkering et al. excluded a
direct role for cholesterol in inducing epigenetic changes but rather
pointed to mevalonate as a direct inducer of trained immunity.7 Mitroulis
et al.,8 however, showed that the whole cholesterol pathway is upregu-
lated during ‘training’ of immune cells to support the cholesterol
demand, by forcing cellular cholesterol biosynthesis (increased
HMGCoAR) and cholesterol uptake (increased LDLR) and limiting cho-
lesterol efflux (decreased ABCA1). Surprisingly, Christ et al.10 showed
that trained immunity occurs also in myeloid cells deprived of the LDLR
thus limiting the key role for this pathway in the response. These results,
which might depend on the different stimuli used as trained immunity
inducers, raise the possibility of targeting the mevalonate pathway with
statins to dampen trained immunity and vascular inflammation. Although
statins possess many pleiotropic effects in vitro, the link between statins
and reduced inflammation in humans appears to be related to their abil-
ity to increase hepatic LDLR expression, thus reducing LDL-C levels
and, as a consequence, inflammation.14 In line with this, Christ et al.
observed increased trained immunity only in mice fed a cholesterol rich
diet, but not on control diet, further supporting the relevance of
cholesterol-driven systemic inflammation for training.
Thus, a LDL-C-independent effect for statins on trained immunity in
humans will be hard to prove, unless epigenetic reprogramming of innate
immune cells could be observed in patients who are not responding to
statins (no changes in LDL-C upon treatment), but in whom a long-term
benefit of the therapy on atherosclerosis and cardiovascular outcomes is
achieved.
Nevertheless, the key role of the NLRP3 inflammasome-IL-1ß axis in
supporting immune training10 suggests this pathway as a potential target
to achieve cardiovascular benefits. In this context, recent data from
the CANTOS trial have shown that canakinumab, an antibody targeting
IL-1ß, significantly decreases the incidence of myocardial infarction in
patients at very high cardiovascular risk,15 an effect independent of
plasma lipid reduction. The ‘toll’ of the robust tuning of the innate
response, however, is a significant increase in the risk of fatal sepsis.15 It is
intriguing to speculate that blocking IL-1ß with canakinumab might also
mitigate the acquisition of a trained phenotype, thus contributing to the
anti-inflammatory and cardiovascular protective effects observed.15
In summary, we now have a clearer picture of molecular mechanisms
controlling trained immunity. The next years of research will have to
focus on a successful translation in the clinical setting of approaches
aimed at controlling trained immunity with the purpose of improving car-
diovascular outcomes; and at the same time, should carefully monitor
any increase in the risk of infections.
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